Kineta has established and is expanding on a diverse pipeline of novel life improving therapies that address critical unmet patient needs. Our research is focused on developing novel immune modulating therapies in neuroscience/pain, virology, immuno-oncology and autoimmune diseases. Kineta‚Äôs AViiD™ Screening Platform is the discovery engine of our innate immune antiviral, vaccine adjuvant and immuno-oncology programs.

ProgramTherapeutic FocusDiscoveryPreclinicalPhase 1APhase 1BPhase 2
Virology/Oncology
AViiD™ Antiviral Discovery PlatformBroad-spectrum antivirals, vaccine
adjuvants and immuno-oncology
Proprietary Screening Platform
Innate Immune AntiviralsBroad spectrum antivirals
Respiratory & emerging viruses
Vaccine
Adjuvants
Pandemic influenza
Immuno-oncologyCancer
LHF-535Viral hemorrhagic fever
(Lassa fever)
Wellcome Trust
Neuroscience/Pain
KCP-400Chronic Pain
Autoimmune
Dalazatide*Lupus, Psoriasis, Vasculitis,
RA, MS, IBD

*Jointly developed by Kineta Inc and its sister corporation KPI Therapeutics Inc.